Loading filters...
Publications per Year (559 total)
1
·
2
·
2
1995
1
·
3
·
4
·
1
·
2
2000
3
·
9
·
8
·
9
·
19
2005
15
·
20
·
13
·
15
·
21
2010
15
·
16
·
21
·
22
·
17
2015
21
·
44
·
31
·
18
·
29
2020
22
·
34
·
38
·
23
·
39
2025
21
·
Loaded
Click to load
50 / 559 papers loaded(scroll for more)
202621 papers
GeneralAdvanced/Metastatic (IV)2026
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.
Hsu CH et al. Lancet Oncol. 2026
GeneralResectable (I-III)2026
PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.
Yang Y et al. Clin Cancer Res. 2026
GeneralAll Stages2026
Prolonged Time to Surgery in Patients With Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Overtoom HCG et al. Ann Surg. 2026
GeneralAdvanced/Metastatic (IV)2026
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.
Sun JM et al. Lancet Oncol. 2026
HER2-positiveAll Stages2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Liu T et al. J Clin Oncol. 2026
GeneralAll Stages2026
Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysis.
Liu S et al. Br J Cancer. 2026
GeneralResectable (I-III)2026
Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?
Leite LF et al. Eur J Cancer. 2026
GeneralAll Stages2026
Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic gastroesophageal adenocarcinoma.
Kamp D et al. Br J Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.
Chen YX et al. Ann Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.
Janjigian YY et al. Ann Oncol. 2026
GeneralAll Stages2026
ISDE guidelines on the management of cT2N0 esophageal cancer.
Kohn GP et al. Dis Esophagus. 2026
GeneralResectable (I-III)2026
Prognostic Impact of Postoperative Complications After Neoadjuvant Therapy Followed by Esophagectomy for Esophageal Cancer: An Exploratory Analysis of Phase III Trial JCOG1109.
Booka E et al. Ann Surg. 2026
GeneralResectable (I-III)2026
Health-related quality of life comparing standard and prolonged time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer: results from the multicenter, randomized, controlled NeoRes II trial.
Holmén A et al. Dis Esophagus. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002).
Chen B et al. J Clin Oncol. 2026
ImmunotherapyResectable (I-III)2026
Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.
Huang TC et al. Br J Cancer. 2026
HER2-positiveAdvanced/Metastatic (IV)2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Shitara K et al. N Engl J Med. 2026
GeneralResectable (I-III)2026
Pathological Outcomes After Uncertain Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
Gangaram Panday SSG et al. Ann Surg. 2026
GeneralResectable (I-III)2026
Patient-derived cancer organoids to tailor personalized treatment strategies in upper gastrointestinal malignancies.
Franken IA et al. Dis Esophagus. 2026
GeneralResectable (I-III)2026
Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis.
Mateos L et al. Br J Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.
Shah MA et al. J Clin Oncol. 2026
GeneralResectable (I-III)2026
Prognostic factors for paraconduit hernia in adult patients post-esophagectomy for cancer: a systematic review.
Abdel Fattah AR et al. Dis Esophagus. 2026
202529 papers
GeneralAll Stages2025
Adjuvant immunotherapy in esophageal squamous cell carcinoma after radiotherapy: retrospective multicentric survival analysis.
Zeng W et al. Dis Esophagus. 2025
GeneralAll Stages2025
Prognostic impact of recurrent laryngeal nerve lymph node metastatic status in thoracic esophageal squamous cell carcinoma.
Yang P et al. Dis Esophagus. 2025
GeneralAll Stages2025
Recurrence patterns following neoadjuvant chemotherapy combined with immunotherapy for esophageal squamous cell carcinoma.
Wang M et al. Dis Esophagus. 2025
GeneralResectable (I-III)2025
Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma.
Walker RC et al. Br J Cancer. 2025
GeneralAll Stages2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.
Zaanan A et al. Lancet Oncol. 2025
GeneralResectable (I-III)2025
Gastric conduit necrosis following esophagectomy: is conduit salvage feasible?
Tankel J et al. Dis Esophagus. 2025
ImmunotherapyAdvanced/Metastatic (IV)2025
Clinical outcomes of pembrolizumab plus chemotherapy for postoperative recurrent esophageal squamous cell carcinoma.
Sugase T et al. Dis Esophagus. 2025
HER2-positiveAdvanced/Metastatic (IV)2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Shitara K et al. N Engl J Med. 2025
GeneralResectable (I-III)2025
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.
van der Wilk BJ et al. Lancet Oncol. 2025
GeneralAll Stages2025
Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles.
Rusidanmu A et al. Dis Esophagus. 2025
GeneralAdvanced/Metastatic (IV)2025
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.
Samalin E et al. ESMO Open. 2025
GeneralResectable (I-III)2025
Proposal of New ypStage Grouping System for Esophageal Squamous Cell Carcinoma Patients who Underwent Neoadjuvant Chemoradiotherapy followed by Surgery.
Park SY et al. Ann Surg. 2025
ImmunotherapyAdvanced/Metastatic (IV)2025
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.
Lu Z et al. J Clin Oncol. 2025
GeneralAll Stages2025
Oncogenic NFE2L2 mutations in plasma ctDNA and tumors are predictors and prognosticators of chemoradiation therapy in resectable esophageal squamous cell carcinoma.
Ko JM et al. Br J Cancer. 2025
GeneralAll Stages2025
Three-field lymph node dissection subsequent to neoadjuvant concurrent chemoradiotherapy in esophageal cancer.
Na B et al. Dis Esophagus. 2025
GeneralAll Stages2025
Causes of death in locally advanced esophageal cancer undergoing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy: a retrospective cohort study.
Liu D et al. Dis Esophagus. 2025
GeneralAll Stages2025
Incomplete neoadjuvant chemo(radio)therapy negatively impacts pathological response and overall survival in locally advanced esophageal cancer.
Kamp D et al. Eur J Cancer. 2025
GeneralAdvanced/Metastatic (IV)2025
Toward standardization in esophageal cancer surgery: patterns of practice across high-volume European centers.
Jones DG et al. Dis Esophagus. 2025
GeneralResectable (I-III)2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Janjigian YY et al. N Engl J Med. 2025
GeneralAdvanced/Metastatic (IV)2025
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.
Janjigian YY et al. Nat Med. 2025
GeneralAdvanced/Metastatic (IV)2025
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI).
Tougeron D et al. Eur J Cancer. 2025
GeneralResectable (I-III)2025
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials.
Okui J et al. Ann Surg. 2025
GeneralAll Stages2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
Shitara K et al. J Clin Oncol. 2025
ImmunotherapyAdvanced/Metastatic (IV)2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.
Metges JP et al. ESMO Open. 2025
GeneralAdvanced/Metastatic (IV)2025
Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy.
Hoeppner J et al. J Clin Oncol. 2025
ImmunotherapyAdvanced/Metastatic (IV)2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
Shitara K et al. J Clin Oncol. 2025
ImmunotherapyAdvanced/Metastatic (IV)2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Kawakami H et al. J Clin Oncol. 2025
GeneralAdvanced/Metastatic (IV)2025
Treatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma.
Igaue S et al. Dis Esophagus. 2025
GeneralAdvanced/Metastatic (IV)2025
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.
Hoeppner J et al. N Engl J Med. 2025